Is this chronic systolic (reduced‑ejection‑fraction) congestive heart failure given a moderately decreased left‑ventricular ejection fraction of 35–40% on echocardiogram?

Yes—This Meets Diagnostic Criteria for Chronic Systolic (HFrEF) Heart Failure

An LVEF of 35–40% on echocardiogram definitively classifies this patient as having heart failure with reduced ejection fraction (HFrEF), provided symptoms or signs of heart failure are present or have been documented previously. 1

---

Diagnostic Framework

The European Society of Cardiology defines HFrEF by three mandatory criteria: 1

1. Symptoms typical of heart failure (breathlessness at rest or on exertion, fatigue, ankle swelling) 1
2. Signs typical of heart failure (tachycardia, pulmonary rales, raised jugular venous pressure, peripheral edema) 1
3. Reduced LVEF (≤40%) 1

The 2022 ACC/AHA/HFSA guidelines similarly define HFrEF as LVEF <40%, placing your patient's 35–40% squarely within this category. 1

---

The Term "Chronic" vs. "Acute"

• The descriptor "chronic" indicates that symptoms have been present for weeks to months, distinguishing this from acute decompensated heart failure (which presents as a medical emergency with life-threatening pulmonary edema). 1
• The term "congestive" is still used in the United States to describe heart failure with evidence of sodium and water retention (congestion), which may resolve with diuretic treatment. 1
• If your patient has never had symptoms, they are classified as Stage B heart failure (structural heart disease without current or previous symptoms), not symptomatic HFrEF. 2

---

Why the 35–40% Range Is Clinically Critical

Device Therapy Eligibility

• LVEF ≤35% is the validated threshold for ICD implantation in primary prevention of sudden cardiac death, based on landmark trials (MADIT-II, SCD-HeFT). 3
• Cardiac resynchronization therapy (CRT) is a Class I recommendation for patients with LVEF ≤35%, sinus rhythm, LBBB morphology, QRS ≥150 ms, and NYHA class II–IV symptoms. 4
• Patients with LVEF in the 35–40% range who meet symptom and QRS criteria should be evaluated for device therapy without delay. 3

Pharmacologic Therapy Mandates

• All four pillars of guideline-directed medical therapy (GDMT) are indicated for LVEF ≤40%: 4

  • ACE inhibitor or ARNI (sacubitril/valsartan preferred) 4
  • Evidence-based beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) 4
  • Mineralocorticoid receptor antagonist (spironolactone or eplerenone) 4
  • SGLT2 inhibitor (dapagliflozin or empagliflozin) 4

• Quadruple therapy should be initiated simultaneously or in rapid sequence, not sequentially over months. 5, 6

---

Prognosis and Risk Stratification

• Patients with LVEF 35–40% have lower mortality than those with LVEF <35%, but still face substantial risk of hospitalization and sudden death. 7
• Symptom severity (NYHA class) correlates poorly with ventricular function; even mildly symptomatic patients with LVEF 35–40% have a relatively high absolute risk of adverse events. 1
• Early, aggressive GDMT can partially reverse systolic dysfunction at this level, but untreated progression leads to irreversible chamber remodeling. 3

---

Common Pitfalls to Avoid

Do Not Delay Device Evaluation While "Optimizing" Medical Therapy

• Device therapy evaluation and GDMT optimization should proceed in parallel, not sequentially. 3
• ICD implantation should be deferred for at least 40 days post-myocardial infarction, but otherwise eligible patients should not wait months for "maximal medical therapy." 4

Do Not Underdose or Discontinue GDMT

• Target doses proven in trials (e.g., enalapril 10–20 mg twice daily, bisoprolol 10 mg daily, spironolactone 25–50 mg daily) are required for mortality benefit. 4
• Forced-titration protocols every 1–2 weeks are essential; accepting suboptimal doses over long periods negates survival benefit. 6, 8
• If LVEF improves to >40%, continue all GDMT indefinitely; discontinuation frequently causes relapse. 1, 4

Avoid Contraindicated Medications

• NSAIDs worsen renal function, promote fluid retention, and blunt ACE-inhibitor efficacy. 4
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) have negative inotropic effects and worsen outcomes in HFrEF. 3, 2

---

Monitoring Protocol

• Before starting an ACE inhibitor, withhold or reduce loop diuretics for 24 hours to prevent first-dose hypotension. 4
• After each dose escalation, check blood pressure, serum creatinine, and potassium at 1–2 weeks, then at 3 months, and every 6 months thereafter. 4
• For spironolactone, recheck potassium and creatinine 4–6 days after initiation; discontinue if potassium ≥5.5 mmol/L. 4
• Serial echocardiography at 3–6 months is essential to assess LVEF trajectory; significant improvement may occur with optimal GDMT, especially in non-ischemic cardiomyopathy. 8

---

Summary Algorithm

1. Confirm symptoms or signs of heart failure (if absent, classify as Stage B). 1, 2
2. Initiate quadruple GDMT immediately: ACE-I/ARNI + beta-blocker + MRA + SGLT2i. 4, 5
3. Titrate to target doses every 1–2 weeks with close laboratory monitoring. 6, 8
4. Evaluate for ICD/CRT if LVEF remains ≤35% after 3 months of optimal therapy. 4, 3
5. Repeat echocardiogram at 3–6 months; continue GDMT indefinitely even if LVEF improves. 1, 8